表紙
市場調查報告書

照護現場 (POC) 分子診斷市場與未來的可能性

The Market and Future Potential for Molecular Point of Care

出版商 Kalorama Information 商品編碼 932010
出版日期 內容資訊 英文 127 Pages
商品交期: 最快1-2個工作天內
價格
照護現場 (POC) 分子診斷市場與未來的可能性 The Market and Future Potential for Molecular Point of Care
出版日期: 2020年03月11日內容資訊: 英文 127 Pages
簡介

照護現場 (POC) 分子診斷系統,設計得比實驗室為基礎的檢驗快速,自現有的照護現場 (POC) 系統被正確。新系統的開發與現有線上選單增加不斷進行。

本報告提供照護現場 (POC) 分子診斷市場與未來的可能性調查分析,發展與趨勢,市場分析,主要企業等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 POC (照護現場) 分子診斷市場發展與趨勢

  • POC (照護現場) 分子診斷的優點和缺點
  • 正當化:靈敏度/特異性的討論
  • 新系統和菜單的增加
  • POC分子診斷系統的投資
  • Raman光譜學的競爭
  • POC市場的中國
  • POC診斷的一般檢驗與分析
  • THERMO的QIAGEN收購
  • POC (照護現場) 分子診斷的零組件技術
  • 新的適應
  • 歐洲的設備法規

第3章 市場分析

  • POC (照護現場) 分子診斷市場分析
  • 呼吸系統用POC (照護現場) 診斷的區分
  • 「NPT分子診斷」市場
  • NPT市場佔有率

第4章 企業簡介

  • ABBOTT LABORATORIES
  • AIDIAN OY
  • AKONNI BIOSYSTEMS
  • BINX HEALTH, INC.
  • BIOCARTIS NV
  • BIOMERIEUX SA
  • CEPHEID
  • CREDO BIOSCIENCE
  • CURETIS NV
  • DIASORIN S.P.A
  • GENMARK DIAGNOSTICS
  • GREINER BIO-ONE GMBH
  • MERIDIAN BIOSCIENCE, INC.
  • MESA BIOTECH, INC.
  • QIAGEN NV
  • QUANTUMDX GROUP
  • QUIDEL CORPORATION
  • ROCHE
  • SEKISUI DIAGNOSTICS LLC
  • T2 BIOSYSTEMS

附錄:新型冠狀病毒感染疾病 (COVID-19) 和POC分子診斷

目錄
Product Code: 20-025

This report provides market sizing, forecasting, trend mapping and competitive analysis for point of care tests using PCR or other molecular technology with fast turnaround times and usability in near-patient settings. Major IVD companies such as Abbott and Roche compete in this segment, influenza competitors Sekisui and Quidel also operate, as do specialty concerns such as Curetis, Biocartis, and a host of small but innovative players.

Molecular point of care or mPOC systems are designed to be faster than lab-based tests while more accurate than existing point of care systems. Development of new systems and menu expansion on existing lines is constant. Kalorama Information defines molecular point of care or mPOC as consisting of devices marketed to customers outside the reference lab that run PCR or other DNA and RNA testing on a device with a small footprint. mPOC systems tend to have a result time fast enough for an office visit or bedside consultation. These systems feature cartridges or reduced preparation steps and limited interpretation of test results.

Less than 10 years from the launch of products this remains a novel test instrument area though with increasing market definition and participation by IVD majors. The market is by no means stable; there is still heavy competition and a need to justify purchases to providers. Kalorama's report provides the current status of this market, including estimates of current sales of near patient molecular systems, forecasts for their future use, and the segments that they are best participating in. Though a global report in scope, regional market share is also provided.

The data in ‘The Market and Future Potential for Molecular Point of Care’ includes information on systems and competitor analysis, as well as data on the size and growth of the market:

  • Current Molecular POC Systems
  • Molecular Point of Care Market: 2019-2024
  • Molecular Point of Care Market Share by Vendor, 2019 ($M, %)
  • Small-Footprint Molecular Point of Care Market, 2019 (%)
  • Geographic Breakout of the Molecular Point of Care Market, 2019 (N. America, Europe, APAC, RoW)
  • Segment Breakout of Molecular Point of Care Market, 2019 (Respiratory vs. Other)
  • Breakout of Molecular Point of Care Market, 2019 (%; Respiratory, Other)
  • Respiratory Segment Breakout, 2019 (Flu, RSV, Strep, Other)
  • Breakout of mPOC Respiratory, 2019 (%; Flu, Strep, RSV, Other)
  • Near Patient Molecular IVD Market: 2019-2024
  • Near Patient Molecular Market Share by Vendor, 2019
  • Company Profiles

Many trends are covered in the report, including menu expansion, disease statistics, the COVID-19 crisis, immunoassay competition and enhancement of those competitive POC systems, emerging markets, new journal studies about the efficacy of mPOC and other trends.

Companies profiled include:

  • Abbott Laboratories
  • Aidian Oy
  • Akonni Biosystems
  • binx health, inc.
  • Biocartis NV
  • bioMérieux SA
  • Cepheid
  • Credo Bioscience
  • Curetis NV
  • DiaSorin S.p.A
  • GenMark Diagnostics
  • Greiner Bio-One GmbH
  • Meridian Bioscience, Inc.
  • Mesa Biotech, Inc.
  • QIAGEN NV
  • QuantuMDx Group
  • Quidel Corporation
  • Roche
  • Sekisui Diagnostics LLC
  • T2 Biosystems

TABLE OF CONTENTS

CHAPTER ONE: EXECUTIVE SUMMARY

  • WHERE IS MOLECULAR POINT OF CARE IN 2020?
  • MOLECULAR POINT OF CARE MARKET ANALYSIS
    • Table 1-1: Molecular Point of Care Market: 2019-2024
    • Figure 1-1: mPOC Market by Disease Indication, 2019 (%; Respiratory, Other)
  • Market Observations
  • “Near-Patient” Molecular Systems Market
    • Table 1-2: Near Patient Molecular Systems Market: 2019-2024
  • CURRENT TRENDS
    • CLIA Waivers and New Standard
    • PAMA Hurts Point of Care Most
    • Immunoassay Are Competitive and Not Going Away
    • Thermo Buys Qiagen
  • MOLECULAR POINT-OF-CARE DIAGNOSTICS DEFINED
  • USAGE OF MOLECULAR POINT OF CARE
  • LEADING MPOC PLATFORMS
    • Table 1-3: Market-Available Molecular POC Diagnostic Platforms
  • TRENDS
  • SCOPE AND METHODOLOGY

CHAPTER TWO: MOLECULAR POINT-OF-CARE MARKET DEVELOPMENT AND TRENDS

  • ADVANTAGES AND DISADVANTAGES OF MOLECULAR POINT OF CARE
    • Table 2-1: Disadvantages of Molecular Point of Care, by Setting
  • JUSTIFICATION: THE SENSITIVITY/SPECIFICITY ARGUMENT
  • NEW SYSTEMS AND MENU EXPANSION
    • Molecular POC Enters STI with Binx Approval
    • Recent RSV Test Approvals Add Revenue Lines to Respiratory
    • Spartan Bioscience Pushing to Commercialize Personalized Heart Test
    • Ontera Developing Single-Pore Sensor for Sepsis, TB, and Zika Diagnostic Testing
    • QuantuMDx and SpeeDx Collaborate on Battery-Operated SDi Test
      • Table 2-2: Recent Menu Expansions for Hospital and POC Molecular Platforms (Vendor, Platform, Menu Addition, Time to Results, CLIA-waiver, US/EU Availability)
  • INVESTMENT IN MPOC SYSTEMS
    • EU Researchers Awarded €3M to Develop POC Molecular Tests
    • Scope Fluidics AST System Sees Investment
    • Other Recent Investments
  • COMPETITION FROM RAMAN SPECTROSCOPY?
  • CHINA AS A POC MARKET
  • COMMON TESTS AND ANALYTES IN POC DIAGNOSTICS
  • THERMO'S QIAGEN ACQUISITION
    • Table 2-3: Complementary Diagnostic Products Offered by Thermo Fisher, Qiagen
  • COMPONENT TECHNOLOGIES OF MOLECULAR POINT-OF-CARE DIAGNOSTICS
    • Microfluidics
    • qPCR
    • Microarrays
    • Isothermal Amplification
    • Test Automation
    • Primers and Probes
    • Detection
    • Next-Generation Sequencing
    • MOLECULAR DIAGNOSTICS
    • Real-Time PCR (qPCR)
    • Isothermal Amplification Methods
    • Line Probe Assays
    • Next-Generation Sequencing
    • APPLICATIONS AND POTENTIAL APPLICATIONS FOR MOLECULAR POINT-OF-CARE
    • Major Testing Applications for Molecular POC Diagnostics
    • Influenza
    • Hospital-Acquired Infections (HAIs)
    • Strep A
    • Respiratory Syncytial Virus (RSV)
  • EMERGING APPLICATIONS
    • Zika
    • Other Respiratory Infections
    • Group B Streptococcus
    • Human Papillomavirus
    • Herpes Simplex Virus
    • Vaginitis
    • Tuberculosis
    • Malaria
    • Other Tropical and Neglected Diseases
    • Cancer
  • EUROPEAN DEVICE REGULATIONS NEARING

CHAPTER THREE: MARKET ANALYSIS

  • MOLECULAR POINT OF CARE MARKET ANALYSIS
    • Table 3-1: Molecular Point of Care Market: 2019-2024
    • Table 3-2: Molecular Point of Care Market Share by Vendor, 2019 ($M, %)
    • Figure 3-1: Small-Footprint Molecular Point of Care Market, 2019 (%)
    • Table 3-3: Geographic Breakout of the Molecular Point of Care Market, 2019 (N. America, Europe, APAC, RoW)
    • Table 3-4: Segment Breakout of Molecular Point of Care Market, 2019 (Respiratory vs. Other)
    • Figure 3-2: Breakout of Molecular Point of Care Market, 2019 (%; Respiratory, Other)
  • Respiratory Molecular Point of Care Segmentation
    • Table 3-5: Respiratory Segment Breakout, 2019 (Flu, RSV, Strep, Other)
    • Figure 3-3: Breakout of mPOC Respiratory, 2019 (%; Flu, Strep, RSV, Other)
  • “NEAR PATIENT MOLECULAR” MARKET
    • Table 3-6: Near Patient Molecular IVD Market: 2019-2024
  • Market Share Near Patient
    • Table 3-7: Near Patient Molecular Market Share by Vendor, 2019

CHAPTER FOUR: COMPANY PROFILES

  • ABBOTT LABORATORIES
  • AIDIAN OY
  • AKONNI BIOSYSTEMS
  • BINX HEALTH, INC.
  • BIOCARTIS NV
  • BIOMÉRIEUX SA
  • CEPHEID
    • Molecular Healthcare-Acquired Infection (HAI) Testing
    • Molecular Sexual Health and Women's Health Testing
    • Molecular Critical Infectious Disease Testing
    • Molecular Oncology/Genetics Testing
  • CREDO BIOSCIENCE
  • CURETIS NV
  • DIASORIN S.P.A
  • GENMARK DIAGNOSTICS
  • GREINER BIO-ONE GMBH
  • MERIDIAN BIOSCIENCE, INC.
  • MESA BIOTECH, INC.
  • QIAGEN NV
  • QUANTUMDX GROUP
  • QUIDEL CORPORATION
  • ROCHE
  • SEKISUI DIAGNOSTICS LLC
  • T2 BIOSYSTEMS

APPENDIX: COVID-19 AND MOLECULAR POC

  • CDC RESPONSE CREATES OPPORTUNITY
  • COVID-19'S UNIQUE CHALLENGE
  • MPOC STEPS IN?
  • LIST OF MPOC TESTS UNDER DEVELOPMENT
    • Table A-1: mPOC-based Coronavirus Announced Tests in Development